Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Griffiths

Showing results (1181-1190 of 1,887) with videos related to

Pageof 189
Sort By:
Haematologica|May 22, 2008
Mutations affecting mRNA splicing are the most common molecular defect in patients with familial hemophagocytic lymphohistiocytosis type 3Alessandra Santoro, Sonia Cannella, Antonino Trizzino, et al.
Archives of Disease in Childhood|March 6, 1998
An unusually severe phenotype for familial adenomatous polyposisD M Eccles, P W Lunt, Y Wallis, et al.
Critical Reviews in Oral Biology and Medicine : an Official Publication of the American Association of Oral Biologists|March 6, 1998
Update on oral lichen planus: etiopathogenesis and managementC Scully, M Beyli, M C Ferreiro, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2007
Congenital abnormalities and clinical features associated with Wilms' tumour: a comprehensive study from a centre serving a large populationA Ng, A Griffiths, T Cole, et al.
Mechanisms of Ageing and Development|July 13, 2004
Retinoic acid receptor alpha expression and cutaneous ageingRachel E B Watson, J Arjuna Ratnayaka, Rebecca C C Brooke, et al.
JAMA Dermatology|May 26, 2018
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical TrialsPeter Foley, Kenneth Gordon, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trialAndrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Integrative Medicine Research|September 3, 2020
Traditional and complementary medicine for promoting healthy ageing in WHO Western Pacific Region: Policy implications from utilization patterns and current evidenceVincent C H Chung, Charlene H L Wong, Claire C W Zhong, et al.
Journal of Drugs in Dermatology : JDD|August 21, 2018
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two YearsChristopher E M Griffiths, Kim A Papp, Alexa B Kimball, et al.
Journal of the American Academy of Dermatology|April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trialKim A Papp, Joseph F Merola, Alice B Gottlieb, et al.
Pageof 189

Showing results (1181-1190 of 1,887) with videos related to

Sort By:
Pageof 189
Haematologica|May 22, 2008
Mutations affecting mRNA splicing are the most common molecular defect in patients with familial hemophagocytic lymphohistiocytosis type 3Alessandra Santoro, Sonia Cannella, Antonino Trizzino, et al.
Archives of Disease in Childhood|March 6, 1998
An unusually severe phenotype for familial adenomatous polyposisD M Eccles, P W Lunt, Y Wallis, et al.
Critical Reviews in Oral Biology and Medicine : an Official Publication of the American Association of Oral Biologists|March 6, 1998
Update on oral lichen planus: etiopathogenesis and managementC Scully, M Beyli, M C Ferreiro, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2007
Congenital abnormalities and clinical features associated with Wilms' tumour: a comprehensive study from a centre serving a large populationA Ng, A Griffiths, T Cole, et al.
Mechanisms of Ageing and Development|July 13, 2004
Retinoic acid receptor alpha expression and cutaneous ageingRachel E B Watson, J Arjuna Ratnayaka, Rebecca C C Brooke, et al.
JAMA Dermatology|May 26, 2018
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical TrialsPeter Foley, Kenneth Gordon, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trialAndrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Integrative Medicine Research|September 3, 2020
Traditional and complementary medicine for promoting healthy ageing in WHO Western Pacific Region: Policy implications from utilization patterns and current evidenceVincent C H Chung, Charlene H L Wong, Claire C W Zhong, et al.
Journal of Drugs in Dermatology : JDD|August 21, 2018
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two YearsChristopher E M Griffiths, Kim A Papp, Alexa B Kimball, et al.
Journal of the American Academy of Dermatology|April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trialKim A Papp, Joseph F Merola, Alice B Gottlieb, et al.
Pageof 189